Clinical Trial

Impact of Conventional Treatments and Clinical Variables on Thyroid Cancer

Study acronym: THY-CANC

Recruiting

Summary

DTC has a generally favorable prognosis. The possibility to discriminate between patients with aggressive tumors and those with a more indolent behavior may reduce the need for unnecessary treatments. Aim of this observational study is to evaluate how anamnestic, clinical, and histopathological variables may influence the outcome of the enrolled patients, both regarding morbidity and mortality and in terms of therapeutic choices. The study aims to evaluate the prognostic impact of the therapeutic interventions in terms of efficacy and regarding the appearance of adverse events.

Protocol Amendment History 2 amendments

This ClinicalTrials.gov record has been amended 2 times since 2023-03-01; most recent amendment 2025-08-01.

Trial Details

NCT Number	NCT05752604
Lead Sponsor	Istituto Auxologico Italiano
Conditions	Thyroid Cancer
Enrollment	3,000 participants
Start Date	2022-07-12
Primary Completion	2032-03-08 (estimated)
Study Completion	2042-03-08 (estimated)
Updated on ClinicalTrials.gov	2025-08-03